Valmark Advisers’s AbbVie ABBV Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $2.6M | Sell |
10,340
-690
| -6% | -$148K | 0.03% | 227 |
|
|
2026
Q1 | $2.4M | Sell |
11,030
-237
| -2% | -$52.6K | 0.03% | 225 |
|
|
2025
Q4 | $2.57M | Sell |
11,267
-95
| -0.8% | -$21.6K | 0.03% | 207 |
|
|
2025
Q3 | $2.63M | Buy |
11,362
+169
| +2% | +$34.4K | 0.03% | 191 |
|
|
2025
Q2 | $2.08M | Buy |
11,193
+1,430
| +15% | +$266K | 0.03% | 218 |
|
|
2025
Q1 | $2.05M | Buy |
9,763
+1,236
| +14% | +$240K | 0.03% | 205 |
|
|
2024
Q4 | $1.52M | Buy |
8,527
+1,044
| +14% | +$192K | 0.02% | 249 |
|
|
2024
Q3 | $1.48M | Buy |
7,483
+890
| +13% | +$166K | 0.02% | 243 |
|
|
2024
Q2 | $1.13M | Buy |
6,593
+402
| +6% | +$66.6K | 0.02% | 259 |
|
|
2024
Q1 | $1.13M | Sell |
6,191
-125
| -2% | -$21.5K | 0.02% | 251 |
|
|
2023
Q4 | $979K | Sell |
6,316
-526
| -8% | -$76.7K | 0.02% | 259 |
|
|
2023
Q3 | $1.02M | Buy |
6,842
+437
| +7% | +$64.2K | 0.02% | 225 |
|
|
2023
Q2 | $863K | Sell |
6,405
-57
| -0.9% | -$8.36K | 0.02% | 248 |
|
|
2023
Q1 | $1.03M | Buy |
6,462
+623
| +11% | +$95.2K | 0.02% | 217 |
|
|
2022
Q4 | $944K | Sell |
5,839
-60
| -1% | -$9.2K | 0.02% | 221 |
|
|
2022
Q3 | $792K | Buy |
5,899
+191
| +3% | +$27.4K | 0.02% | 215 |
|
|
2022
Q2 | $874K | Buy |
5,708
+381
| +7% | +$58.2K | 0.02% | 214 |
|
|
2022
Q1 | $864K | Buy |
5,327
+2,336
| +78% | +$339K | 0.02% | 223 |
|
|
2021
Q4 | $405K | Buy |
2,991
+208
| +7% | +$24.6K | 0.01% | 306 |
|
|
2021
Q3 | $300K | Sell |
2,783
-433
| -13% | -$49.5K | 0.01% | 325 |
|
|
2021
Q2 | $362K | Buy |
3,216
+367
| +13% | +$41.3K | 0.01% | 311 |
|
|
2021
Q1 | $308K | Buy |
2,849
+628
| +28% | +$67.2K | 0.01% | 322 |
|
|
2020
Q4 | $238K | Buy |
+2,221
| New | +$213K | ﹤0.01% | 320 |
|
|
2019
Q4 | – | Sell |
-5,288
| Closed | -$400K | – | 241 |
|
|
2019
Q3 | $400K | Buy |
5,288
+261
| +5% | +$17.9K | 0.01% | 167 |
|
|
2019
Q2 | $366K | Buy |
5,027
+3
| +0.1% | +$236 | 0.01% | 164 |
|
|
2019
Q1 | $405K | Buy |
5,024
+2,248
| +81% | +$184K | 0.01% | 148 |
|
|
2018
Q4 | $256K | Buy |
2,776
+29
| +1% | +$2.55K | 0.01% | 178 |
|
|
2018
Q3 | $260K | Buy |
2,747
+2
| +0.1% | +$190 | 0.01% | 172 |
|
|
2018
Q2 | $254K | Buy |
2,745
+74
| +3% | +$7.23K | 0.01% | 166 |
|
|
2018
Q1 | $253K | Sell |
2,671
-8
| -0.3% | -$879 | 0.01% | 165 |
|
|
2017
Q4 | $259K | Buy |
+2,679
| New | +$252K | 0.01% | 161 |
|
Other funds holding ABBV
Valmark Advisers's ABBV Position: Q2 2026 in Review
Valmark Advisers reduced its AbbVie (ABBV) stake by 6.3% in Q2 2026, selling an estimated $148K and leaving 10,340 shares worth $2.6M. The position accounts for 0.03% of the portfolio, ranked #227.
Valmark Advisers first reported a position in ABBV in Q4 2017 and has held it in 31 quarters since. The position peaked at $2.63M in Q3 2025. 4,201 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.
- Valmark Advisers held 10,340 shares of AbbVie worth $2.6M as of Q2 2026.
- Valmark Advisers sold 690 AbbVie shares in Q2 2026, an estimated $148K.
- AbbVie made up 0.03% of Valmark Advisers's portfolio in Q2 2026, its #227 holding.
- Valmark Advisers first reported a position in AbbVie in Q4 2017 and has held it in 31 quarters since.
- Valmark Advisers's AbbVie position peaked at $2.63M in Q3 2025.
- 4,201 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.
Based on Valmark Advisers's 13F filing for Q2 2026, filed 6 Aug 2026.